Serum acetaminophen below treatment line on nomogram
Asymptomatic or improving
Normal AST and ALT at appropriate timing when clinically indicated
Reliable follow up and safety assessment
Post discharge follow up
Repeat AST and ALT within 24 to 72 hours if borderline or symptoms develop
Primary care follow up for accidental overdosing education
Mental health follow up when intentional ingestion
Treatment
Decontamination
Activated charcoal
Dosing
1 g/kg orally
Usual max 50 g
Timing
Within 2 hours for most cases
Consider within 4 hours for massive ingestion
Consider within 4 hours for extended release
Contraindications
Unprotected airway
Active vomiting with aspiration risk
Antidote therapy
N-acetylcysteine indications
Nomogram at or above treatment line
Unknown time with detectable acetaminophen
Delayed presentation with suspected hepatotoxicity
Repeated supratherapeutic ingestion with liver injury
N-acetylcysteine IV standard 3 bag regimen
Loading dose
150 mg/kg in 200 mL over 60 minutes
Second dose
50 mg/kg in 500 mL over 4 hours
Third dose
100 mg/kg in 1000 mL over 16 hours
Infusion volume adjustments
Fluid restriction cases
Pediatrics weight based fluid plans
N-acetylcysteine IV simplified 2 bag regimen
Loading dose
200 mg/kg over 4 hours
Maintenance dose
100 mg/kg over 16 hours
Use only per local protocol or toxicology guidance
N-acetylcysteine oral regimen
Loading dose
140 mg/kg orally
Maintenance doses
70 mg/kg orally every 4 hours
Total 17 doses
Antiemetic support
Ondansetron per local protocol if vomiting threatens completion
N-acetylcysteine stop criteria
Acetaminophen undetectable
AST and ALT improving
INR stable or improving
Clinical status stable
N-acetylcysteine extension criteria
Persistent detectable acetaminophen
Rising AST or ALT
INR rising
Ongoing hepatic failure features
Adverse reactions and mitigation
N-acetylcysteine anaphylactoid reactions
Typical features
Flushing
Urticaria
Bronchospasm
Hypotension
Immediate management
Pause infusion for moderate or severe reaction
Antihistamines for urticaria
Bronchodilator for bronchospasm
Epinephrine if anaphylaxis physiology
Rechallenge strategy
Restart at slower rate after symptom control
Continue NAC when possible due to high benefit
Adjuncts in massive overdose and severe toxicity
Toxicology consultation triggers
Massive ingestion suspected
Early severe metabolic acidosis
Altered mental status within hours
Very high acetaminophen concentration
Extended release ingestion with rising levels
Fomepizole adjunct consideration
Rationale
CYP2E1 inhibition to reduce NAPQI formation
Use only with toxicology guidance
Off label practice in selected massive cases
Hemodialysis consideration
Indications in selected cases
Severe metabolic acidosis refractory to resuscitation
Altered mental status with high acetaminophen concentration
Lactate elevation with shock physiology
N-acetylcysteine dosing during dialysis
Dose adjustments per toxicology guidance
Supportive care and acute liver failure management
Glucose management
Dextrose bolus for hypoglycemia
Dextrose infusion for recurrent hypoglycemia
Coagulopathy management
Vitamin K consideration
Suspected deficiency
Blood products reserved for bleeding or procedures
Encephalopathy management
Airway protection when grade III or IV
Head of bed elevation
Avoid excessive sedation when possible
Liver transplant pathway
Early referral for acute liver failure
King’s College criteria assessment
Transfer to transplant capable center when criteria met or trending toward
Special Populations
Pregnancy
Pregnancy considerations
Antidote benefit
N-acetylcysteine crosses placenta
Early treatment improves maternal and fetal outcomes
Thresholds and algorithms
Same risk stratification principles as nonpregnant adults
Obstetric coordination
Fetal monitoring for viable gestational age when severe maternal illness
Geriatric
Geriatric considerations
Higher risk contexts
Malnutrition
Polypharmacy with combination analgesics
Fluid management
IV NAC volume adjustments for heart failure risk
Disposition
Lower threshold for admission if frailty or poor support
Pediatrics
Pediatric considerations
Dose thresholds
Acute ingestion risk commonly cited at 150 mg/kg or higher
Chronic ingestion risk depends on daily dosing and duration
Antidote dosing
Weight based NAC regimens
Strict fluid volume calculations
Formulation pitfalls
Liquid concentration errors
Caregiver double dosing with multiple products
Background
Epidemiology
Epidemiology essentials
Common cause of acute liver failure in many regions
Frequent unintentional overdoses from combination products
High incidence of delayed presentations in intentional ingestions
Pathophysiology
Mechanism
Normal metabolism pathways
Glucuronidation
Sulfation
Toxic pathway
CYP mediated NAPQI formation
Glutathione depletion
Hepatocellular necrosis
Risk modifiers
CYP2E1 induction by chronic alcohol
Reduced glutathione stores with malnutrition
Clinical phases correlation
Early mitochondrial toxicity in massive ingestions
Early coma possible
Early lactic acidosis possible
Delayed hepatic necrosis timeline
AST and ALT rise after first day
Peak injury day 3 to 4
Therapeutic Considerations
N-acetylcysteine rationale
Glutathione precursor
Detoxifies NAPQI
Additional effects
Improved hepatic blood flow
Antioxidant effects
Time sensitivity
Best outcomes when started within 8 hours
Benefit persists in established liver failure
Activated charcoal rationale
Reduces absorption when early
May reduce need for NAC in borderline cases when given promptly
Evidence framing
N-acetylcysteine for at risk ingestions considered standard of care
Consensus Class I recommendation
Activated charcoal early considered beneficial in appropriate patients
Consensus Class IIa recommendation
Patient Discharge Instructions
copy discharge instructions
Discharge education
Acetaminophen safe use
Avoid more than one acetaminophen containing product at a time
Follow label dosing intervals
Avoid alcohol with frequent acetaminophen use
Follow up plan
Lab recheck timing if arranged
Primary care follow up
Return immediately for
Persistent vomiting
Worsening abdominal pain
Confusion
Yellowing of eyes or skin
Dark urine
New bleeding or easy bruising
Fainting or severe weakness
References
Guidelines and key sources
Clinical guidance sources
American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists position statements on acetaminophen poisoning management
Liver society guidance on acute liver failure and acetaminophen induced liver injury management
Toxicology reference standards for Rumack-Matthew nomogram interpretation
Transplant referral criteria references for King’s College criteria in acute liver failure
Extracorporeal removal guidance resources for massive acetaminophen overdose scenarios
Foundational studies and tools
Rumack-Matthew acetaminophen nomogram original publication and validation work
N-acetylcysteine clinical outcome studies emphasizing early administration
Acute liver failure prognostic criteria development studies
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.